Hepa1-6 Syngeneic Model Service for Liver Cancer

The Hepa1-6 syngeneic model is the most commonly used immunocompetent platform for hepatocellular carcinoma research, engrafting a hepatocyte-like BW7756-derived tumor line with authentic liver-function secretome into syngeneic hosts for immunotherapy, targeted-therapy, and gene-editing studies. Alfa Cytology delivers this benchmark model as a complete preclinical service — authenticated ATCC-line banking, dose-optimized subcutaneous and orthotopic left-lobe implantation, bioluminescence monitoring, and full hepatic histopathology — giving sponsors the field's standard-setting HCC system with the strain and dose discipline its literature demands.

Overview of Hepa1-6 Syngeneic Model for Liver Cancer

Hepa1-6 is the descendant of BW7756 — a hepatoma that arose spontaneously in a C57L mouse — and it was brought into modern laboratory use by Gladys Darlington, whose 1980 Journal of the National Cancer Institute paper documented liver-phenotype expression in cultured mouse hepatoma cells and whose 1987 Methods in Enzymology chapter established the line's canonical culture protocols. Deposited as ATCC CRL-1830, the line displays epithelial morphology, adherent growth, and — unusually among transplantable hepatomas — a living piece of liver physiology: it secretes albumin, alpha-fetoprotein, α1-antitrypsin, and amylase, expresses multiple cytochrome P450 enzymes, and retains an undifferentiated hepatocellular carcinoma phenotype that makes it a dual-purpose tool for oncology and hepatotoxicology alike. Tumorigenicity is thoroughly dose-mapped: in C57BL/6J hosts, subcutaneous inoculation at 5 × 10⁵ cells produces only 10% takes, at 10⁶ cells 20%, and at 2 × 10⁶ cells 90%, with palpable tumors by day 7 at the highest dose and a tumor-bearing median survival of roughly 57 days — a steep dose–response that rewards careful inoculum standardization. Orthotopically, 5 × 10⁶ luciferase-tagged cells in 20 μL implanted into the left liver lobe recreate the hepatic microenvironment, producing trabecular tumors with preserved sinusoidal structures.

Fig 1. Mechanistic and in vivo validation of the USP5-YTHDF1 axis in the Hepa1-6 syngeneic HCC model — USP5 stabilizes YTHDF1 through mTORC1-mediated phosphorylation (co-IP and ubiquitination assays), and in vivo panels show shUsp5 Hepa1-6 tumors with reduced growth, smaller volume/weight, suppressed USP5/YTHDF1 expression and improved anti-PD-L1 sensitivity with survival benefit. (Shao, Na, et al., 2025)

The model's immunology is as instructive as its biology. A landmark multiplex-imaging comparison of syngeneic HCC models found Hepa1-6 tumors to be the most immune-infiltrated of the panel — dense CD4⁺, CD8⁺, and FoxP3⁺ T-cell infiltrates, abundant F4/80⁺ macrophages of an M1-like character, low MDSC burden, and even tertiary lymphoid structures composed of B220⁺, CD4⁺, and CD8⁺ cells, the structures correlated with improved prognosis in human HCC. The functional consequence is striking: orthotopic Hepa1-6 tumors frequently clear even without checkpoint blockade, and anti-PD-1-treated and control cohorts alike can survive the full eight-week observation window — a robustness that is simultaneously the model's charm and its caution, since reviewers note its microenvironment is not fully representative of human HCC. Two design nuances deserve respect: the line is C57L/J-lineage, so C57BL/6 implantation — however common in the literature — carries a documented haplotype mismatch that can depress orthotopic take rates (3 of 7 in one careful study) and confound immune interpretation; and the standard flank dose of 2 × 10⁶ cells should not be assumed interchangeable across protocols. Within those guardrails, Hepa1-6 has carried some of the decade's most cited liver-cancer studies — METTL3 loss driving sorafenib resistance through FOXO3-mediated autophagy, GDF15-targeting CRISPR nanocapsules reprogramming the immunosuppressive microenvironment of orthotopic disease, and the HDAC8-inhibitor-plus-anti-PD-L1 combination work that produced multi-month tumor-free survival — making it a versatile, deeply annotated workhorse for modern HCC research.

Cell Line Information: Hepa1-6

Hepa1-6 (ATCC CRL-1830; Cellosaurus CVCL_0327; RIKEN RCB1638; Cytion 400474) is the BW7756-derived murine hepatoma line deposited by G. J. Darlington, distributed by the American Type Culture Collection and international repositories. Luciferase-tagged Hepa1-6-Luc derivatives are commercially available for orthotopic bioluminescence studies. Core characteristics are compiled below.

Our Services

Engaging Alfa Cytology for the Hepa1-6 syngeneic model places the field's reference HCC workflow under one accountable team: authenticated ATCC-provenance banks are maintained at low passage with the documented 1:2–1:6 split discipline, hosts are selected with deliberate strain logic (C57BL/6 by default, C57L/J where strict syngeneicity is required), subcutaneous inocula are standardized against the published dose–response curve, and orthotopic left-lobe implants — surgical or ultrasound-guided — are followed by scheduled bioluminescence imaging through treatment arms ranging from checkpoint inhibitors to gene-editing nanocarriers, with terminal hepatic histopathology and immune profiling delivered as an audit-ready data package.

Workflow of Hepa1-6 Syngeneic Model Construction

Hepa1-6 studies succeed or fail on two disciplines no other liver line demands quite so starkly: dose-standardized inocula and deliberate strain selection. Around those pillars, the subcutaneous and orthotopic formats follow the platform's published geometry.

1. Cell preparation and quality control: Hepa1-6 or Hepa1-6-Luc cells are expanded at low passage in DMEM + 10% FBS with the documented split rhythm, confirmed mycoplasma-free, and luciferase activity validated in vitro; inocula are prepared against the published dose–response anchors (10⁶ vs 2 × 10⁶ flank).
2. Host selection and acclimation: C57BL/6 mice (standard practice) or C57L/J mice (strict syngeneicity), typically 6–8 weeks of age, are sourced, quarantined, and acclimated in a specific-pathogen-free barrier facility, with the strain decision documented in the study record.
3. Implantation: subcutaneous route. 2 × 10⁶ cells in 0.1 mL sterile PBS are injected into the flank to exploit the 90% take tier; the site is compressed briefly on needle withdrawal, and palpable tumors are expected within about 7 days.
4. Implantation: orthotopic liver route. Under isoflurane anesthesia with perioperative buprenorphine, a left subcostal laparotomy exposes the left lateral lobe, and 5 × 10⁶ cells in 20 μL PBS are injected into the hepatic parenchyma; an ultrasound-guided variant reduces anesthesia and recovery time with comparable growth kinetics.
5. Closure and postoperative care: The lobe is returned, the abdomen is closed in layers, and mice recover with 72-hour analgesic coverage and daily monitoring of weight and activity.
6. Randomization and treatment: Flank studies are randomized at 150–250 mm³ (typically day 7–10) and orthotopic cohorts at a defined post-implantation interval; checkpoint inhibitors (e.g., anti-PD-1 at 200 μg i.p. three times weekly), targeted agents, or nanocarrier formats are dosed per protocol.
7. Longitudinal monitoring: Tumors are measured by caliper on the protocol cadence; luciferase-tagged cohorts undergo bioluminescence imaging after intraperitoneal D-luciferin injection on IVIS-class systems, with ultrasound as an anatomical complement for orthotopic disease.
8. Endpoint analysis and reporting: At termination, tumors and livers are resected and weighed; tissues undergo H&E with hepatic histology (trabecular pattern, sinusoidal preservation), immunohistochemistry (CD8, FoxP3, F4/80, B220, CD31, PD-L1 panels), flow-cytometric tumor-infiltrating-leukocyte profiling where specified, and metastatic organ screening, with all data consolidated into the final report.

Fig 2. Hepa1-6 Syngeneic Model construction workflow.

Case Study-Hepa1-6 Syngeneic Model Development

Alfa Cytology has applied the Hepa1-6 syngeneic platform to preclinical programs spanning checkpoint inhibitor evaluation, epigenetic-drug combinations, targeted-therapy resistance mechanisms, and gene-editing nanocarrier studies in hepatocellular carcinoma. In these engagements, caliper and bioluminescence readouts tracked flank and orthotopic tumor kinetics, while terminal hepatic histopathology with immune-marker panels and flow-cytometric tumor-infiltrating-leukocyte profiling completed the pharmacological and immunological assessment. Study parameters — strain selection, inoculum tier, implantation route, and endpoint panels — are tailored to each program. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

Hepa1-6 is a model of fine tolerances: the wrong dose tier, a casual strain choice, or an unbalanced checkpoint arm quietly degrades the study. Alfa Cytology fields the dose discipline, strain logic, hepatic microsurgery, and immunological literacy this line demands, making the Hepa1-6 / Hepa1-6-Luc syngeneic model a dependable backbone for your liver cancer program.

• ATCC-documented provenance (CRL-1830), with low-passage banking and the Darlington split discipline.
• Published dose–response anchoring, standardizing inocula against the 10⁶/2 × 10⁶ take tiers.
• Deliberate strain selection, with C57L/J available where strict syngeneicity matters.
• Both orthotopic modalities — surgical and validated ultrasound-guided left-lobe implantation.
• Immune-infiltration literacy, fluent in the model's tertiary-lymphoid-structure and tumor-clearing phenotype.
• Modern therapeutic precedent, from HDAC8 combinations to CRISPR nanocarrier delivery.
• IACUC-compliant, documentation-rich operations delivering audit-ready records throughout the study.

Contact Us

If your liver cancer program requires the field's most commonly used immunocompetent platform, contact us today to discuss Hepa1-6 / Hepa1-6-Luc study design, strain and dose strategy, and endpoint panels with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology looks forward to advancing your next preclinical study.

For research use only. Not intended for any clinical use.